Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b 4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study (PSORIATYK SCALP). J of Skin 2025, 9 (2), s528. https://doi.org/10.25251/skin.10.supp.528.